The treatment literature typically hasn't paid much attention to "gateway drugs" other than nicotine and cannabis. But often, early experimentation with altered consciousness and intoxication involves substances we don't necessarily think of. Especially for persons too young to access more common drugs – or living in areas where they are not readily available – these atypical substances may be a wide open door to intoxication.
Featuring: Dr. Samantha King, CCSA Research and Policy Analyst
Objective: This webinar aims to provide insights into the European ketamine market and will expand on health-related harms caused by non-medical ketamine use.